CLRB Cellectar Biosciences, Inc. Insider Trading

COO Longcor Jarrod adds 8,680 shares at $2.88, expanding stake 74% while stock trades 78% below 52-week high in unprofitable biotech.

COO Longcor Jarrod purchased nearly 8,700 shares at a discount, increasing his position by approximately three-quarters—a substantial commitment at a price substantially below the stock's 52-week high. This is his third open-market purchase in the past 36 months, demonstrating a consistent pattern of buying rather than selling at this company. His prior two purchases at Cellectar showed mixed results: one delivered solid gains over the following quarter, while the other declined, indicating his timing at this company has been inconsistent even when buying at lower price levels. The company itself remains unprofitable with recent quarterly losses, making this purchase notable as buying into fundamental weakness rather than strength. The combination of a senior executive accumulating shares while the company faces losses and the stock trades deeply depressed suggests either confidence in a turnaround or exposure to meaningful downside if the operational challenges persist.

CEO James Caruso buys 8,680 shares as CLRB stock trades 78% below 52-week high amid ongoing losses.

CEO James Caruso is adding materially to his stake, acquiring shares that represent three-quarters of his existing holdings at a time when Cellectar remains unprofitable with significant quarterly operating losses. The stock is trading far below its 52-week high, creating a backdrop where an insider buy might suggest conviction—but the insider's track record offers caution: his prior open-market purchase at this company saw the stock decline in the following month before eventually recovering, a conflicting pattern that offers no clear signal about his timing ability. Cellectar's financial fundamentals remain challenged, with the company burning cash and posting substantial losses, leaving little room to interpret this purchase as a vote of confidence in near-term turnaround. This is only Caruso's second open-market purchase in the 36-month window, and the stock's price action since his last buy—early losses followed by longer-term gains—suggests even prior conviction did not translate into reliable foresight. Without independent positive catalysts or financial improvement, this buy alone does not warrant investor optimism.

CEO James Caruso buys 10,000 shares at $4.99; stock down -94.7% from $90.60 high; cluster buy pattern emerges with 2 other insiders in 14 days.

CEO James Caruso purchased 10,000 shares (10.0K shares) at $4.99 on 2025-07-02, increasing his holdings by 610.5%, while the stock trades at $4.80—down -94.7% from its 52-week high of $90.60 and -42.4% over the past 30 days. The company reported negative full-year net income of $-6,604,029.00, indicating ongoing unprofitability. This buy occurs as part of a cluster pattern with 2 other insiders purchasing within the past 14 days, suggesting coordinated or reactive accumulation during a period of sharp price deterioration. The timing and magnitude of the purchase relative to the stock's collapse and the company's negative earnings warrant investor scrutiny into whether this reflects management's assessment of undervaluation or signals additional business headwinds not yet reflected in market pricing.

CFO Kolean Chad J bought 5,000 CLRB shares at $4.99 as part of cluster buy; stock down 94.7% from $90.60 high, company unprofitable with $-6.6M net income

Kolean Chad J, Chief Financial Officer, purchased 5,000 shares at $4.99 on 2025-07-02, increasing his holdings from 1,418 to 6,418 shares (+352.6%). This transaction is part of a cluster buy pattern with 2 other insiders purchasing within the past 14 days, indicating coordinated insider acquisition activity. The stock has declined 94.7% from its 52-week high of $90.60 to the current price of $4.80, and the company reported full-year net income of $-6,604,029.00, demonstrating material unprofitability. The CFO's purchase at this depressed price level, combined with simultaneous buying by other insiders, warrants investor scrutiny of whether this reflects management's assessment of fundamental value or broader market concerns about the company's trajectory.

COO Jarrod Longcor bought 10,000 shares at $4.99 on 2025-07-02; stock down -94.7% from 52-week high of $90.60, up 361.3% holdings.

Longcor, the Chief Operating Officer, purchased 10,000 shares at $4.99, increasing his holdings by 361.3% from 2,768 to 12,768 shares. The timing is notable: his prior buy at CLRB on 2025-01-10 generated a 90d return of +2822.9%, indicating this insider has successfully timed prior accumulations at this ticker. However, the current backdrop is stark—the stock has collapsed -94.7% from its 52-week high of $90.60 and is down -42.4% over the trailing 30 days, coinciding with an unprofitable fiscal year (net income of $-6,604,029.00). A cluster pattern is present, with 2 other insiders also buying within the past 14 days. The combination of a demonstrated track record of well-timed buys at this ticker, significant personal capital deployment, and coordinated insider accumulation during a severe drawdown warrants investor scrutiny into management's confidence in recovery and any non-public information that may be driving the coordinated activity.

COO Longcor Jarrod purchased 30,000 shares of CLRB at $0.28 on 2025-01-10; stock now -92.2% from 52-week high.

Longcor Jarrod, Chief Operating Officer, purchased 30,000 shares at $0.28 per share, increasing his holdings by 56.5% from 53,141 to 83,141 shares. The transaction occurred at a price dramatically depressed relative to the 52-week high of $122.10, with the current price of $9.50 representing a -92.2% decline from that peak. The company reported net income of $-14.7M in its most recent full fiscal year, indicating sustained unprofitability. This acquisition by a senior executive during a period of severe equity drawdown and operational losses presents a factual data point requiring investor review of the company's operational trajectory and the executive's underlying rationale.